 |
|
|
|
This month we would like to know...
In your opinion which of the following components of healthcare reform will have the most significant impact, positive or negative, on your organization's management of its pharmacy program?
| a) |
Expanded access to coverage for more Americans |
| |
|
| b) |
New regulatory path for biosimilar approval |
| |
|
| c) |
Increased Medicaid drug rebating |
| |
|
| d) |
Enhanced support for comparative effectiveness research |
| |
|
| e) |
Closure of Medicare Part D 'doughnut hole' |
| |
|
| f) |
Enhanced funding for health information technology |
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
|
|
| |
Cotrimoxazole tied to bleeding in older patients on warfarin
In older patients treated with warfarin, the use of cotrimoxazole is associated with a higher risk of upper gastrointestinal (UGI) tract hemorrhage than other common antibiotics, according to research published in the April 12 issue of the Archives of Internal Medicine, as reported by HealthDay News. More... |
|
Lamotrigine may be most effective antiepileptic drug
Of 10 antiepileptic drugs (AEDs) studied in older adults with epilepsy, lamotrigine closely followed by levetiracetam is the most effective, as measured by 12-month retention and freedom from seizures, while oxcarbazepine is consistently less effective than other AEDs, according to research published in the April issue of the Archives of Neurology, as reported by HealthDay News. More... |
Niacin superior to ezetimibe in decreasing CIMT
Patients with coronary heart disease (CHD) or CHD equivalent on stable statin monotherapy treated with the addition of extended-release niacin have significant decreases in carotid intima-media thickness (CIMT) compared with those who had ezetimibe added to their stable statin treatment, according to a study published online April 14 in the Journal of the American College of Cardiology, as reported by HealthDay News. More... |
FMCP tabs winners of P&T and poster competition
The Board of Trustees of the Foundation for Managed Care Pharmacy (FMCP), the educational and philanthropic arm of the Academy of Managed Care Pharmacy (AMCP), announced the winners in the 10th Annual AMCP/FMCP National Student Pharmacist Pharmacy & Therapeutics (P&T) Competition, and FMCP Best Student Pharmacist and Best Resident or Fellow Poster Contests. The awards were presented in April at AMCP�s 22nd Annual Meeting & Showcase in San Diego, Calif. More... |
Some anticonvulsants may raise suicide risk
Anticonvulsant agents have important therapeutic benefits. However, both the healthcare provider and patient need to remain cognizant of associated risks, according to results of a study published in the April 13, 2010, edition of the Journal of the American Medical Association. More... |
Low-dose colchicine found to be as effective as high-dose regimen for early gout flares
Low-dose oral colchicine is just as effective as high-dose colchicine in reducing pain associated with early acute gout flare, but with a safety profile statistically indistinguishable from placebo, according to a study published in the April issue of Arthritis & Rheumatism, the official journal of the American College of Rheumatology. More... |
|
|
|
| In the Pipeline |
| FDA Pipeline preview, April 2010 (Miglustat, Insulin human inhalation powder, APF530, Exenatide LAR, Pirfenidone, ACU-4429, L-asparaginase, Alpha1-proteinase inhibitor, LIPO-102, QPI-1002/I5NP, MA09-hRPE, ARC1779, Ciprofloxacin dry powder inhaler, CK-2017357, GVAX Pancreas Vaccine) |
|
|
| Clinical Meeting Coverage |
|
|
|
|
| |
